Boston Scientific Corp. (BSX) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Boston Scientific’s revenue went from $9.1B in fiscal 2016 to $20.1B in fiscal 2025, growth of about 9.2% a year.
Net income in fiscal 2025 was $2.9B, a net margin of 14.4%; the best year in this period was 2019 with $4.7B.
Over the twelve months to September 30, 2026, revenue was $21.1B and net income $3.5B.
Free cash flow was $3.7B in fiscal 2025 and positive in 9 of the 10 years shown.
The diluted share count rose 9% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.1B | $20.1B | $16.7B | $14.2B | $12.7B | $11.9B | $9.9B | $10.7B | $9.8B | $9.0B | $9.1B |
| Gross profit | $14.6B | $13.9B | $11.5B | $9.9B | $8.7B | $8.2B | $6.4B | $7.6B | $7.0B | $6.5B | $6.0B |
| Operating income | $3.9B | $3.6B | $2.6B | $2.3B | $1.6B | $1.2B | -$80M | $1.5B | $1.5B | $1.3B | $447M |
| Net income | $3.5B | $2.9B | $1.9B | $1.6B | $642M | $985M | -$115M | $4.7B | $1.7B | $104M | $347M |
| EPS (diluted) | $2.36 | $1.94 | $1.25 | $1.07 | $0.45 | $0.69 | $-0.08 | $3.33 | $1.19 | $0.08 | $0.25 |
| R&D | $2.2B | $2.1B | $1.6B | $1.4B | $1.3B | $1.2B | $1.1B | $1.2B | $1.1B | $997M | $920M |
| Revenue growth | — | +19.9% | +17.6% | +12.3% | +6.7% | +19.9% | −7.7% | +9.3% | +8.6% | −0.3% | +12.5% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.2B | $4.5B | $3.4B | $2.5B | $1.5B | $1.9B | $1.5B | $1.8B | $310M | $1.4B | $1.2B |
| Capital spending | -$903M | -$876M | -$790M | -$711M | -$588M | -$554M | -$376M | -$461M | -$316M | -$319M | -$376M |
| Free cash flow | $3.3B | $3.7B | $2.6B | $1.8B | $938M | $1.3B | $1.1B | $1.4B | -$6M | $1.1B | $806M |
| Dividends paid | — | — | $0 | $28M | $55M | $55M | $28M | $0 | $0 | — | — |
| Buybacks | — | — | — | — | $0 | $0 | $535M | $0 | $0 | — | $0 |
| Stock-based pay | $313M | $299M | $266M | $233M | $220M | $194M | $170M | $157M | $140M | $127M | $116M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $2.0B | $414M | $865M | $928M | $1.9B | $1.7B | $217M | $146M | $188M | $196M |
| Debt | — | $12.0B | $11.2B | $9.6B | $9.3B | $9.5B | $9.5B | $10.4B | $7.1B | $5.6B | $5.7B |
| Equity | — | $24.2B | $21.8B | $19.3B | $17.6B | $16.6B | $15.3B | $13.9B | $8.7B | $7.0B | $6.7B |
| Total assets | — | $43.7B | $39.4B | $35.1B | $32.5B | $32.2B | $30.8B | $30.6B | $21.0B | $19.0B | $18.1B |
| Shares (diluted) | 1.45B | 1.49B | 1.49B | 1.46B | 1.44B | 1.43B | 1.42B | 1.41B | 1.40B | 1.39B | 1.38B |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 69.1% | 69.0% | 68.6% | 69.5% | 68.8% | 68.8% | 65.0% | 71.0% | 71.4% | 71.3% | 65.7% |
| Operating margin | 18.7% | 18.0% | 15.5% | 16.4% | 13.0% | 10.1% | -0.8% | 14.1% | 15.3% | 14.2% | 4.9% |
| Net margin | 16.6% | 14.4% | 11.1% | 11.0% | 5.1% | 8.3% | -1.2% | 43.8% | 17.0% | 1.1% | 3.8% |
| FCF margin | 15.8% | 18.2% | 15.8% | 12.6% | 7.4% | 11.1% | 11.4% | 12.8% | -0.1% | 12.2% | 8.9% |
| ROIC | — | 8.5% | 6.4% | 6.5% | 3.8% | 4.4% | -0.2% | 5.0% | 7.5% | 8.0% | 2.9% |
| ROE | — | 12.0% | 8.5% | 8.1% | 3.6% | 5.9% | -0.8% | 33.9% | 19.1% | 1.5% | 5.1% |
Frequently asked questions
What is Boston Scientific’s annual revenue?
$20.1B in fiscal 2025 and $21.1B over the twelve months to September 30, 2026.
How much profit does Boston Scientific make?
Net income was $2.9B in fiscal 2025 (net margin 14.4%).
Is Boston Scientific’s revenue growing?
Yes: revenue rose 19.9% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.